{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang KL"],"funding":["Shin Kong Wu Ho-Su Memorial Hospital"],"pagination":["18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7819176"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Background
To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1-3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC).Methods
This phase I study followed the rule of traditional 3 + 3 design. Major eligibility included: (1) patients with advanced HCC unsuitable for surgery, radiofrequency ablation or transarterial chemoembolization, or who failed after prior local-regional treatment; (2) failure on sorafenib or no grant for sorafenib from health insurance system. Eligible patients with advanced HCC received axitinib for total 8 weeks during and after RT. Three cohorts with axitinib dose escalation were planned: 1 mg twice daily (level I), 2 mg twice daily (level II) and 3 "],"journal":["Radiation oncology (London, England)"],"pubmed_title":["Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial."],"pmcid":["PMC7819176"],"funding_grant_id":["SKH-8302-106-DR-27"],"pubmed_authors":["Huang YY","Huang SC","Ko HL","Chi KH","Lin YM","Chi MS","Yang KL"],"additional_accession":[]},"is_claimable":false,"name":"Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.","description":"Background
To investigate maximum tolerated dose (MTD) of axitinib, a selective vascular endothelial growth factor receptor 1-3 inhibitor, in combination with radiotherapy (RT) for advanced hepatocellular carcinoma (HCC).Methods
This phase I study followed the rule of traditional 3 + 3 design. Major eligibility included: (1) patients with advanced HCC unsuitable for surgery, radiofrequency ablation or transarterial chemoembolization, or who failed after prior local-regional treatment; (2) failure on sorafenib or no grant for sorafenib from health insurance system. Eligible patients with advanced HCC received axitinib for total 8 weeks during and after RT. Three cohorts with axitinib dose escalation were planned: 1 mg twice daily (level I), 2 mg twice daily (level II) and 3 ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-27T00:43:21.48Z","creation":"2021-02-21T01:54:59Z"},"accession":"S-EPMC7819176","cross_references":{"pubmed":["33472666"],"doi":["10.1186/s13014-020-01742-w"]}}